Outcome

The outcomes of the systematic review indicate that hyperbaric oxygen therapy (HBOT) shows significant potential in treating inflammatory bowel disease (IBD) specifically Crohn’s disease and ulcerative colitis. Both human and animal studies demonstrate that HBOT substantially reduces inflammation and oxidative stress which are central to IBD pathology.

Introduction

Traditionally used for conditions such as decompression sickness and wound healing hyperbaric oxygen therapy (HBOT) is now being explored as a treatment for inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis. Recent studies have shown promising results with 78% of Crohn’s disease patients and all patients with ulcerative colitis experiencing clinical improvements after HBOT. These studies which include both human and animal models have demonstrated that HBOT can significantly decrease proinflammatory cytokines like IL-1 IL-6 and TNF-α. Additionally markers of oxidative stress were reduced in most cases. Animal studies revealed similar benefits including decreased inflammation and improved histopathological outcomes. Despite some limitations such as lack of control groups and small sample sizes the findings suggest that HBOT may be a valuable adjunctive treatment for patients with severe treatment-resistant IBD. Further research is needed to confirm these results and to better understand HBOT’s effects on inflammation and clinical outcomes in IBD patients.

Results

In the investigation of the efficacy of hyperbaric oxygen therapy (HBOT) for inflammatory bowel disease (IBD) both human and animal studies were reviewed to determine its impact on conditions such as Crohn’s disease and ulcerative colitis.

In human trials clinical improvements were observed in 78% of Crohn’s disease patients and in all ulcerative colitis patients following HBOT. Specifically one study reported a significant decline in proinflammatory cytokines including IL-1 IL-6 and TNF-α among Crohn’s disease patients. A similar trend was seen in ulcerative colitis patients with a notable reduction in IL-6 levels. The therapy also demonstrated minimal adverse events indicating a favorable safety profile.

Animal studies further corroborated these findings showing substantial decreases in various markers of inflammation and oxidative stress. Key reductions were noted in TNF-α IL-1β neopterin and myeloperoxidase activity. Additionally oxidative stress markers such as malondialdehyde and plasma carbonyl content were significantly lowered in most studies despite one report of increased plasma carbonyl levels. HBOT also led to reduced levels of nitric oxide nitric oxide synthase and prostaglandin E2. Histopathologically four animal studies indicated a decrease in edema or colonic tissue weight and eight studies reported microscopic improvements.

These results suggest that HBOT may offer important therapeutic benefits for both human and animal subjects with IBD particularly those with severe treatment-resistant cases. The consistent reductions in inflammation and oxidative stress markers across multiple studies highlight HBOT’s potential as an adjunctive treatment.

Conclusion

In conclusion this systematic review highlights the potential of hyperbaric oxygen therapy (HBOT) as an adjunctive treatment for inflammatory bowel disease (IBD) encompassing both Crohn’s disease and ulcerative colitis. Evidence from both human and animal studies demonstrates that HBOT leads to significant reductions in inflammation and oxidative stress—key factors in IBD pathology. Notably 78% of Crohn’s disease patients and all ulcerative colitis patients showed clinical improvements with HBOT coinciding with decreases in proinflammatory cytokines such as IL-1 IL-6 and TNF-α and markers of oxidative stress. Animal studies corroborate these findings reporting reduced inflammation and improved histopathological outcomes.

These promising outcomes suggest that HBOT may offer a valuable therapeutic option for patients with severe treatment-resistant IBD. Future research should aim for larger controlled clinical trials to confirm these benefits explore the underlying mechanisms and establish standardized treatment protocols. Continued exploration into HBOT may ultimately lead to improved management strategies for IBD providing hope for patients who struggle with this chronic debilitating condition.